EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Artificial intelligence and generative models in hepatology: from large language models to digital pathology in liver disease diagnosis and treatment

Nana Peng, Mary Yue Wang, Sherlot Juan Song, Jimmy Che-To Lai, Vicki Wing-Ki Hui, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Mamatha Bhat, Terry Cheuk-Fung Yip

Clinical and Molecular Hepatology · 01.10.2026 · 32 (4) · e2026.0258

DOI: 10.3350/cmh.2026.0258 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.10.2026. Verfasst von Nana Peng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Liver Diseases, Artificial Intelligence. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Gilead Sciences, Novo Nordisk Canada, Merck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artificial intelligence (AI), particularly foundation and generative models, is reshaping the practice of hepatology through enhanced knowledge synthesis, quantitative and reproducible analysis of multimodal data, and personalized clinical decision support. This narrative review examines the transition from task-specific discrimination AI to large language models (LLMs), multimodal foundation models, and agentic AI. We synthesize evidence from original and validation studies, clinical evaluations, and benchmark studies, as well as expert reviews and regulatory frameworks across metabolic dysfunction-associated steatotic liver disease, chronic hepatitis B, cirrhosis and portal hypertension, hepatocellular carcinoma, and liver transplantation. LLMs can convert free-text notes into structured data, summarize longitudinal electronic health records, support patient education, and retrieve guideline-based information. Retrieval-augmented generation and agentic AI may improve traceability and workflow support, but current evidence is largely retrospective or proof-of-concept. In digital pathology and imaging, discriminative AI has enabled more quantitative and reproducible histologic scoring and biomarker analysis. Pathology and multimodal foundation models offer transferable representations, report generation, and cross-modal reasoning, but hepatology-specific validation remains limited. Key risks include hallucination, automation bias, domain shift across centers and devices, and inequities due to under-representation of patient subgroups. We outline the future directions for safe AI model deployment based on multimodal foundation models, prospective and federated evaluation, lifecycle governance, and continuous monitoring for performance, calibration, and equity. Most generative AI applications in hepatology remain at the proof-of-concept stage, and rigorous prospective validation with human-in-the-loop oversight is required before clinical integration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver DiseasesArtificial IntelligenceHumansLarge Language ModelsGenerative Artificial IntelligenceGastroenterologyLiver NeoplasmsDigital Health

Stichwörter der Autor:innen

Deep learningGenerative artificial intelligenceLarge language modelsSupervised machine learning

Autor:innen und Institutionen

  • Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
  • State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.
  • Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
  • Ajmera Transplant Centre, University Health Network, University of Toronto, Toronto, ON, Canada. mamatha.bhat@uhn.ca.
  • Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China. tcfyip@cuhk.edu.hk.
  • State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China. tcfyip@cuhk.edu.hk.

Förderung

  • Gilead Sciences
  • Novo Nordisk Canada
  • Merck
  • Paladin
  • Roche
  • Eisai
  • Natera
  • AstraZeneca Canada

Zitieren

APA

Peng, N., Wang, M. Y., Song, S. J., Lai, J. C., Hui, V. W., Wong, V. W., Wong, G. L., Bhat, M., & Yip, T. C. (2026). Artificial intelligence and generative models in hepatology: from large language models to digital pathology in liver disease diagnosis and treatment. Clinical and Molecular Hepatology, 32(4), e2026.0258. https://doi.org/10.3350/cmh.2026.0258

Vancouver

Peng N, Wang MY, Song SJ, Lai JC, Hui VW, Wong VW, et al. Artificial intelligence and generative models in hepatology: from large language models to digital pathology in liver disease diagnosis and treatment. Clinical and Molecular Hepatology. 2026;32(4):e2026.0258. doi:10.3350/cmh.2026.0258

BibTeX
@article{Peng2026,
  author = {Peng, Nana and Wang, Mary Yue and Song, Sherlot Juan and Lai, Jimmy Che-To and Hui, Vicki Wing-Ki and Wong, Vincent Wai-Sun and Wong, Grace Lai-Hung and Bhat, Mamatha and Yip, Terry Cheuk-Fung},
  title = {Artificial intelligence and generative models in hepatology: from large language models to digital pathology in liver disease diagnosis and treatment},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  volume = {32},
  number = {4},
  pages = {e2026.0258},
  doi = {10.3350/cmh.2026.0258}
}
Kostenlos starten →